Tracking Parkinson’s:Study Design and Baseline Patient Data by Malek, Naveed et al.
                          Malek, N., Swallow, D., Grosset, K., Lawton, M. A., Marrinan, S., Lehn, A.,
... Grosset, D. (2015). Tracking Parkinson’s: Study Design and Baseline
Patient Data. Journal of Parkinson's disease, 5(4). DOI: 10.3233/JPD-150662
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC
Link to published version (if available):
10.3233/JPD-150662
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via IOS Press at
http://content.iospress.com/articles/journal-of-parkinsons-disease/jpd150662. Please refer to any applicable
terms of use of the publisher
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
Journal of Parkinson’s Disease 5 (2015) 947–959
DOI 10.3233/JPD-150662
IOS Press
947
Tracking Parkinson’s: Study Design
and Baseline Patient Data
Naveed Maleka,∗, Diane M.A. Swallowa, Katherine A. Grosseta, Michael A. Lawtonb,
Sarah L. Marrinanc, Alexander C. Lehnc, Catherine Bresnerd, Nin Bajaje, Roger A. Barkerf ,
Yoav Ben-Shlomob, David J. Burnc, Thomas Foltynieg, John Hardyh, Huw R. Morrisi,
Nigel M. Williamsd, Nicholas Woodj and Donald G. Grosseta on behalf of the PRoBaND
clinical consortium
aDepartment of Neurology, Institute of Neurological Sciences, Southern General Hospital,
Glasgow, UK
bSchool of Social and Community Medicine, University of Bristol, Bristol, UK
cInstitute of Neuroscience, University of Newcastle, Newcastle upon Tyne, UK
dInstitute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics
and Genomics, Cardiff University, Cardiff, UK
eDepartment of Neurology, Queen’s Medical Centre, Nottingham, UK
fDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, Cambridge, UK
gSobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK
hReta Lila Weston Laboratories, Dept of Molecular Neuroscience, UCL Institute of Neurology,
London, UK
iDepartment of Clinical Neuroscience, UCL Institute of Neurology, London, UK
jDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, UK
Abstract.
Background: There is wide variation in the phenotypic expression of Parkinson’s disease (PD), which is driven by both genetic
and epidemiological influences.
Objectives: To define and explain variation in the clinical phenotype of PD, in relation to genotypic variation.
Methods: Tracking Parkinson’s is a multicentre prospective longitudinal epidemiologic and biomarker study of PD. Patients
attending specialist clinics in the United Kingdom with recent onset (<3.5 years) and young onset (diagnosed <50 years of age)
PD were enrolled. Motor, non-motor and quality of life assessments were performed using validated scales. Cases are followed
up 6 monthly up to 4.5 years for recent onset PD, and up to 1 year for young onset PD. We present here baseline clinical data
from this large and demographically representative cohort.
Results: 2247 PD cases were recruited (1987 recent onset, 260 young onset). Recent onset cases had a mean (standard deviation,
SD) age of 67.6 years (9.3) at study entry, 65.7% males, with disease duration 1.3 years (0.9), MDS-UPDRS 3 scores 22.9
(12.3), LEDD 295 mg/day (211) and PDQ-8 score 5.9 (4.8). Young onset cases were 53.5 years old (7.8) at study entry, 66.9%
male, with disease duration 10.2 years (6.7), MDS-UPDRS 3 scores 27.4 (15.3), LEDD 926 mg/day (567) and PDQ-8 score
11.6 (6.1).
Conclusions: We have established a large clinical PD cohort, consisting of young onset and recent onset cases, which is designed
to evaluate variation in clinical expression, in relation to genetic influences, and which offers a platform for future imaging and
biomarker research.
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BACKGROUND
Parkinson’s disease (PD) is the second most com-
mon neurodegenerative disease affecting the elderly,
the prevalence of which is projected to double by 2030,
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which will have significant implications on future
healthcare delivery and economics [1, 2].
Our understanding of the pathogenesis of PD
changed significantly with the discovery of alpha-
synuclein aggregation in Lewy bodies and Lewy
neurites, the neuropathological hallmarks of the dis-
ease, as a central mechanism in the underlying disease
process [3]. From the initial genetic study linking a spe-
cific mutation in the gene coding for alpha-synuclein,
SNCA, to a familial form of PD [4], a variety of
rare genetic mutations including LRRK2, PARK2, and
PINK-1 were subsequently linked to PD. Collectively,
however, these Mendelian genes account for less than
10% of all PD cases in the general population [5]. More
recently, large genome-wide association studies have
collectively identified susceptibility variants at over
18 loci that increase risk for ‘idiopathic’ PD [5–11].
However, in common with other complex traits, the
pathogenesis in the large majority of cases of PD is
expected to be multifactorial, involving a combination
of genetic and environmental risk factors [12].
Differences in the clinical phenotype between
patients with PD linked to Mendelian genes, compared
to sporadic cases, have been recently reviewed [13].
Detailed genotyping will be performed in the current
study, while also examining the role of environmental
influences.
Finding a serum biomarker for PD would be a major
clinical advance, given known diagnostic error rates,
but would have even greater research implications for
early diagnosis and recording of disease progression.
Our study is collecting data in a large cohort of PD
patients to facilitate detailed genetic studies and as
a resource for linked biomarker research. Here we
present the study protocol and descriptive baseline
data, as a background to subsequent analytical reports
emerging from this study.
METHODS
General outline
The study is carried out in accordance with the
Declaration of Helsinki [14] and is supported by
research nurses from the dementia and neurodegener-
ative research network (DeNDRON), a division of the
National Health Service National Institute of Health
Research in the United Kingdom (UK). Grant fund-
ing is from Parkinson’s UK, the national patient care
and research organization. The primary objective is
to define and explain the variation in the clinical
phenotype of Parkinson’s disease. Secondary objec-
tives are: (a) to relate the variation in the clinical
phenotype of PD to genetic influences; (b) to sup-
port additional studies exploring genetic, serum and
imaging biomarkers for the diagnosis, stratification and
progression of PD.
Tracking Parkinson’s is a large prospective, obser-
vational, multicentre project. Patients were recruited
with a clinical diagnosis of PD, corroborated by
Queen Square Brain Bank criteria [15] and supported
by neuroimaging performed when the diagnosis was
not firmly established clinically. Both drug-naı¨ve and
treated patients, aged 18 to 90 years were eligible.
Young onset cases were diagnosed at or below age 50
years, and recent onset cases were diagnosed within
the preceding 3.5 years. Baseline recruitment is com-
plete and patients are currently engaged in 6 monthly
follow up. Recruitment of first degree relatives, to a
target of 840 unaffected siblings, is underway. All
participants have LRRK2 and GBA mutation carrier
status assessed with young onset cases also screened
for PARK2 and PINK1 mutations. Exclusion crite-
ria were severe comorbid illness e.g severe COPD
or symptomatic heart failure that would not allow
patient participation in clinic visits, other degenerative
forms of parkinsonism e.g. progressive supranuclear
palsy, or, parkinsonism attributable to significant cere-
brovascular disease eg. lower body parkinsonism with
prominent vascular history (patients with ‘inciden-
tal’ small vessel disease on brain imaging were not
excluded). Patients with drug-induced parkinsonism
were excluded, but drug-unmasked PD was allowed if
justified by abnormal functional dopaminergic imag-
ing with dopamine transporter (DaT) single photon
emission computed tomography (SPECT) or fluo-
rodopa (18F) positron emission tomography (F-DOPA
PET).
72 sites in the UK providing secondary care treat-
ment for PD patients as part of the UK National Health
Service (NHS) (and in selected sites, their linked aca-
demic institutions) are participating, with multicentre
ethics committee and local research and development
department approvals.
Data handling
Data capture by the local clinical and research team
allowed direct entry to a secure anonymized web-based
electronic data capture system, backed by a paper case
record form. Data collection for clinical assessments
followed the standards of the Clinical Data Inter-
change Standards Consortium (CDISC) PD user guide,
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which incorporates common data elements developed
by the US National Institute of Neurological Disor-
ders and Stroke. Missing and erroneous data points
were identified and pursued by central study coordina-
tors. Statistical analysis was performed in Bristol. All
genetic data are generated, analyzed and stored at the
central laboratory in Cardiff.
Clinical assessments
Clinical assessments were made in out-patient
clinics, using standardized and validated scales, to
document the motor and non-motor features, quality
of life and drug responsiveness of the enrolled sub-
jects. Home visits were performed in a few remote
settings. Study follow up visits were 6-monthly with
more detailed observations at 0, 18, 36 and 54 months
(Fig. 1). Levodopa equivalent daily dose (LEDD) was
calculated using established formulas for equivalence
[16, 17]. Orthostatic hypotension was defined as a sys-
tolic drop ≥20 mmHg or diastolic drop ≥10 mmHg.
Montreal cognitive assessment (MoCA) was adjusted
for education years and mild cognitive impairment
defined as a score 21–25, and dementia defined
as a score <21) [18]. Non-motor symptom severity
(NMSS) was graded according to predefined sever-
ity categories: mild 1–20, mod 21–40, severe 41–70
and >70 very severe [19]. Depression and anxiety
were identified from scores above 6 in the Leeds
hospital anxiety and depression scale (LADS) [20].
Epworth sleep scale (ESS) was used to define exces-
sive daytime sleep when the score exceeded 9 [21].
Rapid eye movement (REM) sleep behaviour disor-
der (RBD) was defined from a score above 4 [22].
Constipation was defined as laxative use or less than
one bowel motion per day. Impaired olfaction was
defined as an UPSIT (University of Pennsylvania smell
identification test) <24/40 for age for age 60 years and
older, and <29/40 for under 60 years old [23].
Genetic analysis
Blood samples were collected at all sites at study
entry: an ethylene diamine tetraacetic acid (EDTA)
sample for DNA extraction and an acid citrate dextrose
(ACD) sample for cryopreservation of peripheral blood
lymphocytes at the European Centre for Cell Cultures
(ECACC) in Wiltshire, England to generate a long
term backup resource. All DNA samples are stored
for analysis and distribution at the study’s centralized
laboratory at Cardiff University, Wales.
In all PD patients the G2019S mutation at LRRK2 is
genotyped using a Kompetitive Allele Specific Poly-
merase (KASP) assay (LGC Genomic solutions) and
the GBA mutation carrier status established by DNA
sequencing of all coding exons. The genes PARK2
and PINK1 are screened for mutations using DNA
sequencing and multiplex ligation-dependent probe
amplification (MLPA) (MRC Holland) in all young
onset PD patients. All DNA samples will also be
genotyped using the Illumina Human Core Exome
array, which has been supplemented with custom con-
tent. This will allow for the analysis of approximately
250,000 common single nucleotide polymorphisms
(SNPs) and 250,000 rare variants, plus over 27,000
custom variants selected due to their previous implica-
tion in a range of neurodegenerative, neurological, and
psychiatric disorders.
Proteomic analysis
Serum samples are stored in 6 aliquots at study entry
only in young onset cases; every 18 months in recent
onset patients; and every 3 years in siblings of patients.
Fig. 1. Assessments and timeline for recent onset patients. Visits occur every 6 months, with repeated observations and blood sampling every
18 months.
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Storage is at –80◦ centigrade. A proteomic biomarker
research program is coordinated in Oxford, England,
involving samples from the current study and other
ongoing UK PD cohort studies.
Statistical analysis
Sample sizes were calculated pragmatically using
known UK incidence rates and NHS clinic activity
levels, but sufficient to allow prognostic modelling
involving random splits of the samples into training
and validation cohorts. Standard statistical methods
(survival curves and Cox proportional hazard models)
and more complex multivariable models such as multi-
level, latent class and/or growth curve models will
be used to examine for heterogeneity in the present-
ing features and natural history of PD. Collaboration
with other linked cohort studies, such as the Oxford
Parkinson Disease Centre (OPDC) Discovery cohort,
has been established and will be used for replication
of findings for external validation [18].
RESULTS
Demographic characteristics
The average age of recent onset cases at diagnosis
was 66.3 years, with mean disease duration from diag-
nosis of 1.3 years at the time of recruitment. 43.9% of
these were recruited within 1 year of diagnosis, 28.5%
between 1 and 2 years and 27.6% between 2 and 3.5
years.
The average age of young onset cases at diagnosis
was 43.3 years, with a mean disease duration from
diagnosis of 10.2 years at the time of recruitment.
In both groups, males outnumbered females by
approximately 2:1. Young onset cases, as expected,
had a longer disease duration from symptom onset
to diagnosis (2.2 years, SD 3.4) compared to 1.8
years (SD 2.9) in recent onset patients. Additional
demographic data are in Table 1 and Supplementary
Table 1.
Comorbid disease
Recent onset cases had more than double the comor-
bid cardiovascular disease, cerebrovascular disease
and vascular risk factors compared to young onset
cases (Supplementary Table 2). With the exception of
lung cancer, cancer diagnoses overall were also more
Table 1
Baseline demographics in 2247 PD patients
Variable Recent onset Young onset
N = 1987 N = 260
Age in years
At study entry 67.6 (9.3) 53.5 (7.8)
At diagnosis 66.3 (9.3) 43.3 (5.7)
At symptom onset 64.4 (9.8) 41.6 (6.8)
Years since diagnosis 1.3 (0.9) 10.2 (6.7)
Male sex 65.7% 66.9%
Handedness (right/left/mixed) 85.6/9.6/4.8% 87.5/9.0/3.5%
Ethnicity
White 1920 (98.0%) 244 (95.3%)
Asian or Asian British 19 (1.0%) 10 (3.9%)
Black or Black British 14 (0.7%) 2 (0.8%)
Mixed 4 (0.2%) 0
Other 3 (0.2%) 0
BMI (kg/m2) 27.0 (4.7) 27.5 (5.7)
Data are mean (standard deviation) or percentage, BMI = body mass
index.
prevalent in the recent onset group. The rates of breast
cancer though were similar between the groups.
Family history
In young onset cases, 25.5% had a family history of
PD, which was more frequent than in recent onset cases
(19.9%) (p = 0.038). A family history of dementia did
not differ significantly between recent and young onset
cases (p = 0.076), and a family history of stroke was
similar across groups (Table 2).
Neuroimaging
Data relating to the mode and results of neuroimag-
ing undertaken as part of the patient’s routine clinical
care prior to recruitment were extracted. The propor-
tion of patients with brain computed tomography (CT),
magnetic resonance imaging (MRI), FP-CIT SPECT
and F-DOPA PET imaging are detailed in Supplemen-
tary Table 3.
Clinical observations
Baseline lying/standing pulse, and blood pressure in
cases are detailed in Supplementary Table 4. Ortho-
static hypotension (Table 4) was more frequent at
baseline in recent onset cases (17.2 vs. 11.3%). BMI
(Table 1) in both groups was also slightly above the
normal range (defined as 18.5–24.9) [24].
Taking into account the longer disease duration of
young onset cases, the following features are noted.
Young onset cases had higher MDS-UPDRS Part 3
scores (Table 3), as well as total MDS-UPDRS scores
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Table 2
Family history of Parkinson’s disease, dementia, and stroke in 2247
PD patients
Positive family history Recent onset Young onset
n = 1987 n = 260
Parkinson’s disease
Only one affected 311 (15.8%) 51 (19.7%)
More than 1 affected 82 (4.2%) 15 (5.8%)
Recessive PD historya 38 (1.9%) 4 (1.5%)
Dominant PD historyb 355 (18.0%) 62 (23.9%)
Dementia or Alzheimer’s disease
Mother only 159 (8.1%) 13 (5.0%)
Maternalc 28 (1.4%) 2 (0.8%)
Father only 46 (2.3%) 6 (2.3%)
Paternald 10 (0.5%) 1 (0.4%)
Stroke
Mother only 68 (3.5%) 12 (4.6%)
Maternalc 12 (0.6%) 1 (0.4%)
Father only 74 (3.8%) 8 (3.1%)
Paternald 4 (0.2%) 1 (0.4%)
Data are number (percentage), aOnly siblings affected, bAny other
relative affected (could also include a sibling affected), cMother
and another maternal family member affected, dFather and another
paternal family member affected.
Table 3
Baseline clinician scored items in 2247 PD patients
Variable Recent onset Young onset
N = 1987 N = 260
UPDRS
Part 1 9.3 (5.4) 13.8 (7.3)
Part 2 9.8 (6.6) 17.6 (9.5)
Part 3 22.9 (12.3) 27.4 (15.3)
Part 4 0.8 (1.8) 5.7 (5.0)
Total 42.7 (19.8) 63.6 (29.6)
Motor subtype
Tremor dominant 46% 27.5%
Postural instability gait difficulty 41% 63%
Indeterminate 13% 9.6%
Hoehn and Yahr stage, median (IQR) 2 (1-2) 2 (1.5–2.5)
LEDD 295 (211.3) 926 (566.6)
Montreal cognitive assessment
Normal 53.4% 55.5%
Mild cognitive impairment 36.8% 36.2%
Dementia 9.8% 8.3%
Data are mean (standard deviation) or percentage unless otherwise
stated. UPDRS = Movement Disorder Society unified Parkinson’s
disease rating scale; IQR = Interquartile range; LEDD = levodopa
equivalent daily dose.
at study entry (mean 63.6) compared to recent onset
cases (mean 42.7). Despite these differences both
groups had a median Hoehn and Yahr stage of 2. In
recent onset cases, 36.8% had mild cognitive impair-
ment (MCI) and 9.8% dementia at study entry. Young
onset cases had a similar frequency of MCI (36.2%)
to the recent onset cases but a lower frequency of
dementia (8.3%). The spectrum and severity of both
motor features and motor complications, disability and
Table 4
Non-motor features in 2247 PD patients
Variable Recent onset Young onset
n = 1987 n = 260
Non-motor symptom severity
Mild 37.1% 19.7%
Moderate 34.5% 19.1%
Severe 19.6% 27.3%
Very severe 8.8% 33.9%
Restless legs 23.6% 28.3%
Depression 23.6% 43.0%
Anxiety 24.0% 50.0%
Excessive daytime sleepiness 24.5% 49.0%
REM sleep behaviour disorder 43.7% 60.0%
Constipation 33.6% 33.7%
Hyposmia 75.3% 75.9%
Orthostatic hypotension 17.2% 11.3%
REM = Rapid Eye Movement.
cognitive impairment in recent and young onset cases,
according to the clinical impression of severity index
for Parkinson’s disease, is shown in Fig. 2.
Results of patient scored questionnaires at study
entry assessing non-motor symptoms are in Tables 4
and 5. Overall non-motor symptoms were common
in both groups, but young onset patients reported a
greater frequency and/or severity of these at study
entry, including sleep disturbance, depression, anxiety,
autonomic symptoms (except constipation and laxa-
tive use) and impulsive-compulsive behaviours, with
perceived poorer quality of life compared to recent
onset patients, while again noting their longer disease
duration.
Medication use
Over 90% of patients were prescribed antiparkinson
medication at study entry (Fig. 3). The mean LEDD
was 295 mg/day in recent onset cases and 926 mg/day
in young onset cases, reflecting disease duration.
Withdrawal rates
Study retention has been successful to date (Table 6).
Fourteen cases were excluded from the recent onset
cohort following diagnostic revision: 4 were later diag-
nosed with PSP, one with multiple sclerosis, one with
MSA, one with essential or dystonic tremor, one with
corticobasal degeneration, one had a normal FP-CIT
SPECT scan, and 5 without a clear diagnosis. One case
was excluded from the young onset cohort following a
subsequent normal FP-CIT SPECT scan.
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Fig. 2. Clinical impression of severity index scores in 2247 PD patients. Recent onset cases had a significantly shorter disease duration than
young onset cases, explaining their milder motor features and disability, while the cognitive pattern was more equal, given the greater risk of
cognitive impairment with age.
Table 5
Impulsivity and autonomic features in 2247 PD patients
Variable Recent onset Young onset Controlsa
n = 1987 n = 260
Impulsivity
Gambling 1.6% 23.2% 0.7%
Sex 5.3% 25.0% 3.5%
Buying 3.7% 25.7% 2.1%
Eating 5.4% 21.7% 10.5%
Medication 1.5% 8.4% NA
Hobbyism 9.7% 37.6% 11.9%
Punding 5.5% 17.1% 2.1%
Walkabout 1.1% 6.4% 0.7%
One or more 22.7% 67.6% 20.3%
PDSS 109 (23.5) 91.8 (28.7) 120.7 (21.0)
SCOPA – AUT
Gastrointestinal 3.0 (2.5) 4.2 (3.2) 1.4 (1.6)
Urinary 4.7 (3.3) 5.3 (3.6) 3.9 (2.4)
Cardiovascular 0.7 (1.1) 1.1 (1.3) 0.3 (0.6)
Thermoregulatory 1.6 (1.8) 3.1 (2.5) 1.8 (2.0)
Pupillomotor 0.4 (0.7) 0.6 (0.8) 0.4 (0.7)
Sexual male 1.9 (2.0) 1.7 (1.8) 1.3 (1.7)
Sexual female 1.6 (1.7) 1.4 (1.4) 1.4 (1.5)
Total autonomic score 11.8 (7.1) 15.6 (9.2) 8.8 (5.4)
aImpulsivity Control data from Weintraub et al. [25]. Sleep distur-
bance control data from Chaudhuri et al. [26]. PDSS = Parkinson’s
Disease Sleep Scale. SCOPA-AUT, SCales for Outcomes in PArkin-
sons disease – AUTonomic control data from Visser M et al. [27].
DISCUSSION
Young onset cases
Impulsivity data from such a large cohort of young
onset cases has not been reported. The presence of
one or more impulsive/compulsive behaviours in two-
thirds of our young onset cases considerably exceeds
the prevalence rate found in our recent onset cases, and
prior reports [28]. This may relate to the known greater
risk of impulse control disorders (ICD) in young onset
PD [29] and frequent use of dopamine agonists. The
multiplicity of involved domains from the ICD ques-
tionnaire was striking in these young onset cases.
Family history of PD was more likely in young onset
than recent onset cases, consistent with known higher
rates of genetic mutations in young onset disease [30]
but the difference between groups was not striking.
One in 4 young onset patients had at least one other
family member with PD, compared to less than 1 in
5 recent onset cases. This familial association of PD
also applied when considering cases where more than
1 family member was affected by PD, matching prior
reports [31].
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Fig. 3. Antiparkinson medication at baseline in 2247 PD patients. Most patients were already on antiparkinson medication at recruitment. Young
onset cases had a longer disease duration than recent onset cases, which will affect usage rates and the proportions on more than one drug class.
MAOB-I = monoamine oxidase B inhibitor; COMT-I = catechol-O-methyl transferase inhibitor.
Table 6
Rates and reasons for study withdrawal in 2247 PD patients
Variable Recent onset Young onset
n = 1987 n = 260
Withdrawn 156 (7.9%) 11 (4.2%)
Time to withdrawal years 1.4 (0.7) 0.7 (0.6)
Reasona
Intercurrent illness 14.7% 9.1%
Patient died 18.0% 27.3%
Patient choice 43.6% 27.3%
Other 23.7% 36.4%
Data are number (percentage). aPercentage of those withdrawn.
We did not identify an increased likelihood of a
dementia diagnosis in relatives of young onset PD
cases, compared to our recent onset cases, which differs
from earlier reports [32, 33]. Our definition of demen-
tia in relatives depended on patient reporting, without
corroboration from their medical records, matching the
methods of one of those studies [33]. The age cut-off
for defining young onset disease in those studies was
however pragmatically set at a rather older age (60 or
66 years) representing the youngest quintile [32] or
tertile [33] of their series, which may have influenced
their findings.
RBD is proposed as a sensitive pre-motor marker
of PD [34] and can be screened for by using the
RBD screening questionnaire (RBDSQ) [22]. RBDSQ
scores in our young onset cases were slightly worse
than recent onset cases, which is contrary to another
study that found a higher prevalence of RBD in older
patients [35]. Further, the Oxford Discovery study
noted that patients with RBD (47.2% of cases) had a
greater prevalence of non-motor features [36]. RBD
at baseline significantly correlated with an increase
in total UPDRS scores over time in another study
[37]. RBD therefore appears to be a marker of
more advanced neurodegeneration, being described in
patients with more motor complications, a higher rate
of falls, the emergence of cognitive problems and psy-
chotic symptoms, and it may therefore be a predictor
of entering a more advanced stage of disease [38]. The
longer disease duration in our young onset cases may
therefore account for our worse RBDSQ scores.
While our young onset patients reported greater
diagnostic delay (around 4 months longer than recent
onset cases), recall bias affected by their longer dis-
ease duration may have contributed. Somewhat shorter
delays are reported, being 15 months in young onset
patients (aged <46) [39], and under 2 years in most
studies [40, 41]. A timely diagnosis of PD is impor-
tant to initiate necessary treatment and relay prognostic
information, but has greater significance for the early
implementation (in clinical trials) of potential disease
modifying treatments.
Recent onset cases
There is a potential two-way association between
PD and stroke, in both of which oxidative stress may
be pathogenic [42]. In a prospective study, a 1.5 to
2 fold increased risk of developing PD was associated
with previous stroke, with a similarly increased relative
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risk for a first time diagnosis of ischemic stroke in
patients diagnosed with PD [43]. A high prevalence of
vascular disease, and risk factors for this, were present
particularly in our recent onset cases where combin-
ing high cholesterol, hypertension, and diabetes gave
a ‘vascular risk’ rate of around half of cases. Vascu-
lar risk factors are of interest as several are potentially
modifiable. The presence of diabetes as a risk factor
for developing PD is controversial, with one case-
control study showing no increased risk [44], but a
cohort study reporting almost doubling of the risk [45].
The presence of vascular risk factors may modify dis-
ease expression in PD; elevated cardiovascular risk
scores were an independent predictor of higher axial
motor impairments in PD [46]. Hypertension, which
was present in one-third of our recent onset cases,
correlated with impaired cognitive performance (exec-
utive function and verbal memory) in PD in another
study [47]. Continued observation of the relationship
between vascular and parkinsonian features is planned
in the follow-up phase.
Out of four cancer types recorded, the highest rates
were for breast and prostate cancer in our recent onset
cases, with no cases of prostate cancer in our young
onset cases. A recent meta-analysis found no over-
all increased risk of breast or prostate cancer in PD
patients compared to the general population [48]. The
overall higher cancer prevalence in recent onset cases
therefore most likely reflects the known increased inci-
dence rates of most cancers with age [49].
The findings that 13% of recent onset cases had a
mixed motor phenotype is very similar to prior obser-
vations [50]. While tremor was recorded at onset in
approximately three quarters of cases in each group,
PIGD was more likely in young onset cases, proba-
bly due to evolution of motor subtypes [51], which
is important when evaluating the association of early
clinical features and genetic and biomarker traits. For
example, dementia is more likely in cases presenting
with PIGD, compared to tremor dominant or inde-
terminate subtypes, and is also more likely in cases
evolving to a PIGD subtype [52, 53]. Patients with
a PIGD motor subtype also have faster disease pro-
gression [54] and worse health related quality of life
[55].
The proportion of our recent onset cases with mild
cognitive impairment (MCI, 36.8%) and dementia
(9.8%) is similar to the Oxford Discovery cohort, at a
similar disease duration (MCI 40.5%, dementia 11.7%)
using similar methods [18]. These findings are con-
sistent with the ICICLE-PD study which found MCI
in 42.5% at baseline, in an incident cohort, using
Movement Disorder Society level II criteria [56] that
recommend cut-off scores of 1.5 SD below normal val-
ues [57]. Both results are higher than the Parkinson’s
progression marker initiative (PPMI) study (average
disease duration 6.5 months, untreated) [58] where
21.5% had MCI at baseline, 34.2% at 1 year, and
35.5% at 2 years, and may reflect different selection
criteria.
Scores of daytime somnolence were similar to those
reported in cohorts of a similar age (but generally with
a longer disease duration), compared to our recent
onset cases. Worse ESS scores correlate with more
depression, higher disease severity, and higher doses
of dopaminergic agents [59]. A correlation between
daytime somnolence and cognitive impairment is also
reported [60]. Our PD sleep scale (PDSS) scores in
young onset cases (mean 91.8, SD 28.7) were slightly
worse than those previously reported (mean 120.9,
SD 20.0) [61]. While reports of a positive correlation
between severity of sleep disturbance and motor sever-
ity are not uniform [62] some report such an association
[26, 63]. The reported prevalence of RLS in PD is vari-
able, ranging between 5.5 and 27% in European cohort
studies [64], against which our rate was 28.3% in the
young onset cases and 23.6% in recent onset cases, is
at the higher end of this range.
Our SCOPA-AUT results lie between results found
in newly diagnosed, drug naive patients [65] and
those with a longer disease duration in cross-sectional
studies [66, 67]. As well as disease duration, the
prevalence and severity of autonomic symptoms have
been associated with more severe impairments in
motor symptoms, cognition, depression, sleep distur-
bance, psychiatric complications, and the prescription
of dopaminergic drugs [68]. These factors may account
for the higher scores seen in our young onset patients in
all individual components of the SCOPA-AUT, except
sexual function where recent onset patients reported a
greater prevalence of such symptoms.
In keeping with previous reports, a proportion of our
recent onset patients exhibited orthostatic hypotension
(OH) early in the course of disease, as a marker of
autonomic instability. Baseline autonomic dysfunction
may serve as a predictor of cognitive impairment, with
a systolic drop of >10 mmHg at baseline being associ-
ated with 7-fold increased risk of dementia at 4.4 years
in a prospective study [69].
Constipation is of particular interest in PD, as one
marker of autonomic involvement that may predate
motor diagnosis [70, 71]. However around a quarter
of our recent onset cases had 2 or more bowel motions
per day (without laxative use), indicating that constipa-
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tion is not a universal feature, even after the diagnosis
of PD. Our results are consistent with the finding that
the majority of PD patients have only mild colorectal
symptoms [72].
Non-motor symptoms such as constipation, depres-
sion, restless legs, particularly when they cluster
together are now well recognised as early clinical
markers of PD but given that the majority of our
patients reported motor symptoms as a presenting fea-
ture, the inclusion of motor assessments in studies
designed to identify ‘at risk’ subjects would be appro-
priate.
Limitations
One limitation of the study design is that comparison
of recent onset and young onset groups will inevitably
show differences because of different disease duration.
We included a young onset population primarily to
enrich the proportion with known genetic mutations,
given the involvement of siblings and the genetic focus
of the study. While statistically correcting for age, gen-
der and disease duration would aid some comparisons,
it has limited capacity to correct for evolution of dis-
ease characteristics over time.
CONCLUSION
In conclusion, we present the baseline data of a large
clinical research network which is actively following
cases in a combined clinical-laboratory program, eval-
uating variation in the clinical expression of PD which
will be studied in relation to genetic influences. This
offers a platform for serum and imaging biomarker
research. We hope that the scale and linkage of this
research program will help to understand the pathogen-
esis of PD, and identify new pathways leading towards
preventive treatments. The longitudinal follow-up of
our PD cases and siblings is a key component, and will
be the subject of further reports.
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